Hostname: page-component-745bb68f8f-d8cs5 Total loading time: 0 Render date: 2025-01-22T19:51:44.868Z Has data issue: false hasContentIssue false
  • English
  • Français

The Value of Collaboration in Improving Knowledge on Rare Diseases

Published online by Cambridge University Press:  02 December 2014

Kate Bushby
Kate Bushby*
Affiliation:
Newcastle-upon-Tyne, United Kingdom
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Editorial
Information
Canadian Journal of Neurological Sciences , Volume 38 , Issue 3 , May 2011 , pp. 387
Copyright
Copyright © The Canadian Journal of Neurological 2011

References

1 Mah, JK, Selby, K, Campbell, C, et al. A population-based study of dystrophin mutations in Canada. Can J Neurol Sci. 2011;38(3): 465–74.CrossRefGoogle ScholarPubMed
2 Bushby, K, Finkel, R, Birnkrant, DJ, et al. Diagnosis and management of DuchenneMuscular Dystrophy, part 1: diagnosis and pharmacological and psychosocial management. Lancet Neurol. 2010;9(1):77–93.CrossRefGoogle Scholar
3 Bushby, K, Lochmuller, H, Lynn, S, Straub, V. Interventions for muscular dystrophy: molecular medicines entering the clinic. Lancet. 2009;374(9704):1849–56.CrossRefGoogle ScholarPubMed
4 Cunnif, C, Andrews, J, Meaney, FJ, et al. Mutation analysis in a population based cohort of boys with Duchenne or Becker muscular dystrophy. J Child Neurol. 2009;24(4):425–30.CrossRefGoogle Scholar
5 Abbs, S, Tuffery-Giraud, S, Bakker, E, Ferlini, A, Sejersen, T, Mueller, CR. Best practice guidelines on molecular testing in Duchenne and Becker muscular dystrophies. Neuromuscul Disord. 2010 Jun;20(6):422–7.CrossRefGoogle Scholar